Nitric oxide, adenosine deaminase, xanthine oxidase and superoxide dismutase in patients with panic disorder: alterations by antidepressant treatment
Version of Record online: 5 DEC 2005
Copyright © 2005 John Wiley & Sons, Ltd.
Human Psychopharmacology: Clinical and Experimental
Volume 21, Issue 1, pages 53–59, January 2006
How to Cite
Herken, H., Akyol, O., Yilmaz, H. R., Tutkun, H., Savas, H. A., Ozen, M. E., Kalenderoglu, A. and Gulec, M. (2006), Nitric oxide, adenosine deaminase, xanthine oxidase and superoxide dismutase in patients with panic disorder: alterations by antidepressant treatment. Hum. Psychopharmacol. Clin. Exp., 21: 53–59. doi: 10.1002/hup.742
- Issue online: 30 DEC 2005
- Version of Record online: 5 DEC 2005
- Manuscript Accepted: 13 OCT 2005
- Manuscript Received: 25 APR 2005
- Panic Disorder;
- adenosine deaminase;
- xanthine oxidase;
- nitric oxide;
- superoxide dismutase;
- treatment response
In the present study, we aimed to investigate whether nitric oxide (NO) levels and activities of xanthine oxidase (XO), superoxide dismutase (SOD), and adenosine deaminase (ADA) are associated with Panic disorder (PD) as well as impact of psychopharmacological treatments on NO, SOD, ADA, and XO levels in PD.
In this study, 32 patients and 20 healthy controls were included. The serum levels of NO, XO, SOD, and ADA were measured in the patients and controls. The patients were treated with antidepressant.
ADA and XO levels of the patients were significantly higher than the controls. SOD levels of the patients were significantly lower than the controls but the difference was not statistically significant. Although NO levels of the patients were higher than the controls, the difference was not statistically significant. There was no correlation between PAS and the parameters studied (SOD, ADA, XO, and NO) of the patients. After 8 weeks of antidepressant treatment, ADA and SOD activities were increased whereas NO and XO levels decreased significantly.
ADA, XO activity may have a pathophysiological role in PD, and prognosis of PD. Activity of these enzymes may be used to monitor effects of the antidepressant treatment. Copyright © 2005 John Wiley & Sons, Ltd.